CHMP backs Novartis’s Zykadia for first-line use in lung cancer

ZURICH (Reuters) – Novartis’s push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Powered by WPeMatico

Leave a Reply

Your email address will not be published. Required fields are marked *